Shares of drugmaker BioXcel Therapeutics BTAI.O rise 23% to $2.03 premarket
Co says its experimental drug, BXCL501, helped ease symptoms of opioid withdrawal by over 30% in a mid-stage study with 80 adults
Adds that BXCL501 outperformed lofexidine, a non-opioid taken four times a day for withdrawal symptoms
Also notes fewer side effects for BXCL501 vs. lofexidine, including lower rates of low blood pressure and no reported sedation
BTAI fell ~73% in 2025